Adverse reactions to L-asparaginase in oncopediatric patients

Detalhes bibliográficos
Autor(a) principal: Barbosa, Khrisna Fiuza
Data de Publicação: 2019
Outros Autores: Xavier, Rosa Malena Fagundes, Ribeiro, Martamaria de Souza Ferraz, Bendicho, Maria Teresita
Tipo de documento: Artigo
Idioma: por
eng
Título da fonte: Vigilância Sanitária em Debate
Texto Completo: https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/1295
Resumo: Introduction: Adverse drug reaction (ADR) is defined as “any harmful or undesirable and unintended response occurring with medicaments at doses usually employed in humans”. Objective: To describe the adverse reactions to L-asparaginase, developed by oncopediatric patients, accompanied by the Pharmacy Clinic service, in a philanthropic hospital, in Salvador, Bahia, Brazil. Method: This is a cross-sectional, retrospective, descriptive study, in which an analysis of nine electronic medical records of oncopediatic patients was performed using L-asparaginase from June 2017 to February 2018. Results: Among the patients, 66.7% were male and 55.6% were aged ≤ 5 years. Acute lymphoid leukemia was the diagnosis of all patients. 66.7% of the study group presented some type of adverse reaction, pruritus being the most frequent (36%) and in 66.7% of the situations, the drug was suspended. All reactions were reported. Conclusions: The results suggest that special attention is needed in oncopediatric patients, since the possibility of adverse drug reactions is higher. With the performance of the pharmacist in centers of high complexity in Oncology, it is possible to develop strategies and promote actions to prevent or minimize the occurrence of these adverse events during antineoplastic therapy.
id FIOCRUZ-9_3485e2bca626eca853dc6f49d75b08ec
oai_identifier_str oai:ojs.visaemdebate.incqs.fiocruz.br:article/1295
network_acronym_str FIOCRUZ-9
network_name_str Vigilância Sanitária em Debate
repository_id_str
spelling Adverse reactions to L-asparaginase in oncopediatric patientsReações adversas ao medicamento L-asparaginase em pacientes oncopediátricosL-AsparaginaseLeuginaseOncopediatricsAcute Lymphoblastic LeukemiaPharmacovigilanceL-AsparaginaseLeuginaseOncopediátricosLeucemia Linfoblástica AgudaFarmacovigilânciaIntroduction: Adverse drug reaction (ADR) is defined as “any harmful or undesirable and unintended response occurring with medicaments at doses usually employed in humans”. Objective: To describe the adverse reactions to L-asparaginase, developed by oncopediatric patients, accompanied by the Pharmacy Clinic service, in a philanthropic hospital, in Salvador, Bahia, Brazil. Method: This is a cross-sectional, retrospective, descriptive study, in which an analysis of nine electronic medical records of oncopediatic patients was performed using L-asparaginase from June 2017 to February 2018. Results: Among the patients, 66.7% were male and 55.6% were aged ≤ 5 years. Acute lymphoid leukemia was the diagnosis of all patients. 66.7% of the study group presented some type of adverse reaction, pruritus being the most frequent (36%) and in 66.7% of the situations, the drug was suspended. All reactions were reported. Conclusions: The results suggest that special attention is needed in oncopediatric patients, since the possibility of adverse drug reactions is higher. With the performance of the pharmacist in centers of high complexity in Oncology, it is possible to develop strategies and promote actions to prevent or minimize the occurrence of these adverse events during antineoplastic therapy.Introdução: Reação adversa a medicamento (RAM) é definida como “qualquer resposta prejudicial ou indesejável e não intencional que ocorre com medicamentos em doses usualmente empregadas no ser humano. Objetivo: Descrever as reações adversas ao medicamento L-asparaginase, desenvolvidas por pacientes oncopediátricos, acompanhados pelo serviço de Farmácia Clínica, em um hospital filantrópico, de Salvador, Bahia, Brasil. Método: Trata-se de um estudo transversal, retrospectivo, descritivo, no qual foi realizada análise de nove prontuários eletrônicos dos pacientes oncopediátricos, em uso de L-asparaginase no período de junho de 2017 a fevereiro de 2018. Resultados: Entre os pacientes, 66,7% pertenciam ao sexo masculino e 55,6% apresentavam idade ≤ 5 anos. A Leucemia Linfoide Aguda foi o diagnóstico de todos os pacientes. Sessenta e sete vírgula sete por cento (66,7%) do grupo de estudo apresentou algum tipo de reação adversa, sendo prurido a mais frequente (36%) e, em 66,7% das situações, o medicamento foi suspenso. Todas as reações foram notificadas. Conclusões: Os resultados sugerem que é necessária uma atenção especial aos pacientes oncopediátricos, visto que a possibilidade de ocorrer reações adversas a medicamento é mais elevada. Com a atuação do farmacêutico nos centros de alta complexidade em oncologia, é possível desenvolver estratégias e promover ações para prevenir ou minimizar a ocorrência desses eventos adversos, durante a terapia antineoplásica.Instituto Nacional de Controle de Qualidade em Saúde2019-05-31info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion"Peer-reviewed article""Artículo revisado por pares""Artigo avaliado pelos pares"application/pdfapplication/pdfhttps://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/129510.22239/2317-269x.01295Health Surveillance under Debate: Society, Science & Technology ; Vol. 7 No. 2 (2019): May; 46-50Vigilancia en Salud en Debate: Sociedad, Ciencia y Tecnología; Vol. 7 Núm. 2 (2019): Puede; 46-50Vigil Sanit Debate, Rio de Janeiro; v. 7 n. 2 (2019): Maio; 46-502317-269Xreponame:Vigilância Sanitária em Debateinstname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZporenghttps://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/1295/1011https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/1295/1091Copyright (c) 2019 Vigilância Sanitária em Debate: Sociedade, Ciência & Tecnologia (Health Surveillance under Debate: Society, Science & Technology) – Visa em Debatehttps://creativecommons.org/licenses/by-nc-nd/4.0info:eu-repo/semantics/openAccessBarbosa, Khrisna FiuzaXavier, Rosa Malena FagundesRibeiro, Martamaria de Souza FerrazBendicho, Maria Teresita2023-06-27T15:11:12Zoai:ojs.visaemdebate.incqs.fiocruz.br:article/1295Revistahttps://visaemdebate.incqs.fiocruz.br/index.php/visaemdebatePUBhttps://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/oaiincqs.visaemdebate@fiocruz.br || gisele.neves@fiocruz.br2317-269X2317-269Xopendoar:2023-06-27T15:11:12Vigilância Sanitária em Debate - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.none.fl_str_mv Adverse reactions to L-asparaginase in oncopediatric patients
Reações adversas ao medicamento L-asparaginase em pacientes oncopediátricos
title Adverse reactions to L-asparaginase in oncopediatric patients
spellingShingle Adverse reactions to L-asparaginase in oncopediatric patients
Barbosa, Khrisna Fiuza
L-Asparaginase
Leuginase
Oncopediatrics
Acute Lymphoblastic Leukemia
Pharmacovigilance
L-Asparaginase
Leuginase
Oncopediátricos
Leucemia Linfoblástica Aguda
Farmacovigilância
title_short Adverse reactions to L-asparaginase in oncopediatric patients
title_full Adverse reactions to L-asparaginase in oncopediatric patients
title_fullStr Adverse reactions to L-asparaginase in oncopediatric patients
title_full_unstemmed Adverse reactions to L-asparaginase in oncopediatric patients
title_sort Adverse reactions to L-asparaginase in oncopediatric patients
author Barbosa, Khrisna Fiuza
author_facet Barbosa, Khrisna Fiuza
Xavier, Rosa Malena Fagundes
Ribeiro, Martamaria de Souza Ferraz
Bendicho, Maria Teresita
author_role author
author2 Xavier, Rosa Malena Fagundes
Ribeiro, Martamaria de Souza Ferraz
Bendicho, Maria Teresita
author2_role author
author
author
dc.contributor.author.fl_str_mv Barbosa, Khrisna Fiuza
Xavier, Rosa Malena Fagundes
Ribeiro, Martamaria de Souza Ferraz
Bendicho, Maria Teresita
dc.subject.por.fl_str_mv L-Asparaginase
Leuginase
Oncopediatrics
Acute Lymphoblastic Leukemia
Pharmacovigilance
L-Asparaginase
Leuginase
Oncopediátricos
Leucemia Linfoblástica Aguda
Farmacovigilância
topic L-Asparaginase
Leuginase
Oncopediatrics
Acute Lymphoblastic Leukemia
Pharmacovigilance
L-Asparaginase
Leuginase
Oncopediátricos
Leucemia Linfoblástica Aguda
Farmacovigilância
description Introduction: Adverse drug reaction (ADR) is defined as “any harmful or undesirable and unintended response occurring with medicaments at doses usually employed in humans”. Objective: To describe the adverse reactions to L-asparaginase, developed by oncopediatric patients, accompanied by the Pharmacy Clinic service, in a philanthropic hospital, in Salvador, Bahia, Brazil. Method: This is a cross-sectional, retrospective, descriptive study, in which an analysis of nine electronic medical records of oncopediatic patients was performed using L-asparaginase from June 2017 to February 2018. Results: Among the patients, 66.7% were male and 55.6% were aged ≤ 5 years. Acute lymphoid leukemia was the diagnosis of all patients. 66.7% of the study group presented some type of adverse reaction, pruritus being the most frequent (36%) and in 66.7% of the situations, the drug was suspended. All reactions were reported. Conclusions: The results suggest that special attention is needed in oncopediatric patients, since the possibility of adverse drug reactions is higher. With the performance of the pharmacist in centers of high complexity in Oncology, it is possible to develop strategies and promote actions to prevent or minimize the occurrence of these adverse events during antineoplastic therapy.
publishDate 2019
dc.date.none.fl_str_mv 2019-05-31
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
"Peer-reviewed article"
"Artículo revisado por pares"
"Artigo avaliado pelos pares"
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/1295
10.22239/2317-269x.01295
url https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/1295
identifier_str_mv 10.22239/2317-269x.01295
dc.language.iso.fl_str_mv por
eng
language por
eng
dc.relation.none.fl_str_mv https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/1295/1011
https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/1295/1091
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by-nc-nd/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-nd/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Instituto Nacional de Controle de Qualidade em Saúde
publisher.none.fl_str_mv Instituto Nacional de Controle de Qualidade em Saúde
dc.source.none.fl_str_mv Health Surveillance under Debate: Society, Science & Technology ; Vol. 7 No. 2 (2019): May; 46-50
Vigilancia en Salud en Debate: Sociedad, Ciencia y Tecnología; Vol. 7 Núm. 2 (2019): Puede; 46-50
Vigil Sanit Debate, Rio de Janeiro; v. 7 n. 2 (2019): Maio; 46-50
2317-269X
reponame:Vigilância Sanitária em Debate
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Vigilância Sanitária em Debate
collection Vigilância Sanitária em Debate
repository.name.fl_str_mv Vigilância Sanitária em Debate - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv incqs.visaemdebate@fiocruz.br || gisele.neves@fiocruz.br
_version_ 1797042045369450496